Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Buspirone(click to collapse)
1/4 selected
Buspirone
Buspar · Bucapsol
Azapirone (5-HT1A Partial Agonist)
FDA-approved indications
- Generalized anxiety disorder — short-term relief (adults)
Off-label uses
- MDD augmentation
- Social anxiety disorder
- PTSD
Half-life2 to 3 hours
Decision GuideWhen to pick each / when to consider an alternative
Buspirone
Consider when
- GAD when benzodiazepine avoidance desired — FDA-approved for GAD; non-sedating anxiolytic without abuse potential or dependence
- SSRI-induced sexual dysfunction augmentation — 5-HT1A partial agonism may reduce SSRI-induced SD; off-label but evidence-supported
- Elderly anxious patient — no cognitive impairment, no respiratory depression, no fall risk; preferable to benzodiazepines in geriatric population
- SUD comorbidity with anxiety — no abuse potential, not scheduled; safe in substance use disorder populations
- +1 more
Consider an alternative when
- Rapid anxiolytic effect needed — takes 2–4 weeks for onset; cannot be used PRN for acute anxiety episodes
- Prior benzodiazepine use — patients with benzodiazepine experience often report buspirone as ineffective (expectation mismatch)
- Panic disorder — not effective for panic attacks; SSRIs or benzodiazepines preferred for panic
- TID dosing is an adherence barrier — short t½ requires TID dosing; adherence may suffer compared to QD SSRIs
- +1 more
| Axis | Buspirone azapirone |
|---|---|
| Pregnancy | |
Lactation / breastfeeding safety | |